Renal nitric oxide synthase and antioxidant preservation in Cyp1a1-Ren-2 transgenic rats with inducible malignant hypertension

American Journal of Hypertension

Volumn 26, Issue 10, 2013, Pages 1242-1249

  Cunningham, Mark W ^a   Sasser, Jennifer M ^a   West, Crystal A ^a   Milani, Carlo J ^b   Baylis, Chris ^a   Mitchell, Kenneth D ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

angiotensin receptor blocker; aorta; blood pressure; candesartan; hypertension; kidney; superoxide dismutase; total antioxidant capacity

Indexed keywords

ANTIOXIDANT; CANDESARTAN; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRIC OXIDE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; KIDNEY BLOOD FLOW; KIDNEY CORTEX; KIDNEY FUNCTION; KIDNEY MEDULLA; KIDNEY PRESERVATION; MALE; MALIGNANT HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; WESTERN BLOTTING;

ANGIOTENSIN RECEPTOR BLOCKER; AORTA; BLOOD PRESSURE; CANDESARTAN; HYPERTENSION; KIDNEY; SUPEROXIDE DISMUTASE; TOTAL ANTIOXIDANT CAPACITY.;

ANIMALS; ANTIOXIDANTS; BENZIMIDAZOLES; CYTOCHROME P-450 CYP1A1; GLOMERULAR FILTRATION RATE; HYPERTENSION, MALIGNANT; INDOLES; KIDNEY; MALE; NADPH OXIDASE; NITRIC OXIDE SYNTHASE TYPE I; RATS; RATS, TRANSGENIC; TETRAZOLES;

EID: 84890058204     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt096     Document Type: Article

References (33)

1. Kantachuvesiri S, Fleming S, Peters J, Peters B, Brooker G, Lammie AG, McGath I, Kotelevtsev Y, Mullins JJ. Controlled hypertension, a transgenic toggle switch reveals differential mechanism underlying vascular disease. J Biol Chem 2001; 276:36727-36733
2. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res 2000; 86:494-501
3. Kopkan L, Castillo A, Navar LG, Majid DS. Enhanced superoxide generation modulates renal function in ANG II-induced hypertensive rats. AM J Physiol Renal Physiol 2006; 290:F80-F86
4. Nishiyama A, Fukui T, Fujisawa Y, Rahman M, Tian RX, Kimura S, Abe Y. Systemic and regional hemodynamic responses to tempol in angiotensin II-infused hypertensive rats. Hypertension 2001; 37: 77-83
5. Samuni A, Godinger D, Aronovitch J, Russo A, Mitchell JB. Nitroxide blocks DNA scission and protect cells from oxidative damage. Biochemistry 1991; 30:555-561
6. Schnackenberg CG, Wilcox CS. The SOD mimetic tempol restores vasodilation in afferent arterioles of experimental diabetes. Kidney Int 2001; 59:1859-1864
7. Schnackenberg CG, Welch WJ, Wilcox CS. Normalization of blood pressure and renal vascular resistance in SHR with a membranepermeable superoxide dismutase mimetic: Role of nitric oxide. Hypertension 1998; 32:59-64
8. Patterson ME, Mouton CR, Mullins JJ, Mitchell KD. Interactive effects of superoxide anion and nitric oxide on blood pressure and renal hemodynamics in transgenic rats with inducible malignant hypertension. Am J Physiol Renal Physiol 2005; 289:F754-F759
9. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986; 320:454-456
10. Schnackenberg CG. Oxygen radicals in cardiovascular-renal disease. Curr Opin Pharmacol 2002; 2:121-125
11. Wilcox CS, Welch WJ. Interaction between nitric oxide and oxygen radicals in regulation of tubuloglomerular feedback. Acta Physiol Scand 2000; 168:119-124
12. Baylis C. Nitric oxide deficiency in chronic kidney disease. Gottschalk Lecture 2007. Am J Physiol Renal 2008; 294:F1-F9
13. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: Structure, function and inhibition. Biochem J 2001; 357:593-615
14. Szabo AJ, Wagner L, Erdely A, Lau K, Baylis C. Renal neuronal nitric oxide synthase protein expression as a marker of renal injury. Kidney Int 2003; 64:1765-1771
15. Mattson DL, Wu F. Nitric oxide synthase activity and isoforms in rat renal vasculature. Hypertension 2000; 35:337-341
16. Ortiz PA, Garvin JL. Trafficking and activation of eNOS in epithelial cells. Acta Physiol Scand 2003; 179:107-114
17. Nakano D, Pollock JS, Pollock DM. Renal medullary ETB receptors produce dieresis and natriuresis via NOS1. Am J Physiol Renal Physiol 2008; 294: F1205-F1211
18. Pollock JS, Pollock DM. Endothelin and NOS1/nitric oxide signaling and regulation of sodium homeostasis. Curr Opin Nephrol Hypertens 2008; 17:70-75
19. Wu F, Park F, Cowley AW Jr., Mattson DL. Quantification of nitric oxide synthase activity in microdissected segment of rat kidney. Am J Physiol Renal Physiol 1999; 276:F874-F881
20. Smith C, Merchant M, Fekete A, Nyugen HL, Oh P, Tain YL, Klein JB, Baylis C. Splice variants of neuronal nitric oxide synthase are present in rat kidney. Nephrol Dial Transplant 2009; 24:1422-1428
21. Mitchell KD, Bagatell SJ, Miller CS, Mouton CR, Seth DM, Mullins JJ. Genetic clamping of rennin gene expression induces hypertension and elevation of intrarenal Ang II levels of graded severity in Cyp1a1-Ren2 transgenic rats. J Renin Angiotensin Aldosterone Syst 2006; 7:74-86
22. Smith C, Merchant M, Fekete A, Nyugen HL, Oh P, Tain YL, Klein JB, Baylis C. Splice variants of neuronal nitric oxide synthase are present in rat kidney. Nephrol Dial Transplant 2009; 24:1422-1428
23. Suto T, Losonczy G, Qiu C, Hill C, Samsell L, Ruby J, Charon N, Venuto R, Baylis C. Acute changes in urinary excretion of nitrite + nitrate do not necessarily predict renal vascular NO production. Kidney Int 1995; 48:1272-1277
24. Vanourkova Z, Kramer HJ, Huskova Z, Vaneckova I, Opocensky M, Chabova VC, Tesar V, Skaroupkova P, Thumovia M, Dohnalova M, Mullins JJ, Cervenka L. AT1 receptor blockade is superior to conventional triple therapy in protecting against end-organ damage in Cyp1a1-Ren-2 transgenic rats with inducible hypertension. J Hypertens 2006; 24:2465-2472
25. Ortiz RM, Graciano ML, Mullins JJ, Mitchell KD. Aldosterone receptor antagonism alleviates proteinuria, but not malignant HTN, IN cyp1a1-Rens transgenic rats. Am J Physiol Renal Physiol 2007; 293:F1584-F1591
26. Hernandez Schulman I, Zhou MS, Raij L. Cross-talk between angiotensin II receptor types 1 and 2: Potential role in vascular remodeling in humans. Hypertension 2007; 49:270-271
27. Savoia C, Touyz RM, Volpe M, Schiffrin EL. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension 2007; 49:341-346
28. Patterson ME, Mullins JJ, Mitchell KD. Renoprotective effects of neuronal NOS-derived nitric oxide and cyclooxygenase-2 metabolites in transgenic rats with inducible malignant hypertension. Am J Physiol Renal Physiol 2008; 294:F205-F211
29. Kopkan L, Huskova Z, Vanourkova Z, Thumova M, Skaroupkove P, Maly J, Kramer HJ, Dvorak P, Cervenka L. Reduction of oxidative stress does not attenuate the development of angiotensin II-dependent hypertension in Ren-2 transgenic rats. Vascul Pharmacol 2009; 51:175-181
30. Wei Y, Clark SE, Morris EM, Thyfault JP, Uptergrove GM, Whaley-Connell AT, Ferrario CM, Sowers JR, Ibdah JA. Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol 2008; 49:417-428
31. Mattson DL. Importance of renal medullary circulation in the control of sodium excretion and blood pressure. Am J Physiol Regul Integr Comp Physiol 2003; 284:R13-R27
32. Pallone TL, Mattson DL. Role of nitric oxide in regulation of the renal medulla in normal and hypertensive kidneys. Curr Opin Nephrol Hypertens 2002; 11:93-98
33. Zuckerman A, Chander PN, Zeballos GA, Stier CT Jr. Regional renal nitric oxide release in stroke-prone spontaneously hypertensive rats. Hypertension 1997; 30:1479-1486